Category Business

, PCI Pharma

PCI Pharma Acquires Ajinomoto Althea as Part of $1B Investment to Boost U.S. Aseptic Fill-Finish Capacity

PCI Pharma Acquires Ajinomoto Althea as Part of $1B Investment to Boost U.S. Aseptic Fill-Finish Capacity PCI Pharma Services, a globally recognized contract development and manufacturing organization (CDMO) specializing in the development and commercialization of innovative biopharmaceutical therapies, has officially…

Read MorePCI Pharma Acquires Ajinomoto Althea as Part of $1B Investment to Boost U.S. Aseptic Fill-Finish Capacity
Sunflower Therapeutics

Sunflower Therapeutics Announces Sales Agreement with Optimal Biotech Group

Sunflower Therapeutics Announces Sales Agreement with Optimal Biotech Group Sunflower Therapeutics, a public benefit corporation with a mission to transform global access to protein manufacturing capacity, has taken a significant step toward commercial expansion with the announcement of a new…

Read MoreSunflower Therapeutics Announces Sales Agreement with Optimal Biotech Group
Ray Therapeutics

Ray Therapeutics Gets $8M Grant to Work on New Gene Therapy for Vision Loss Disease

Ray Therapeutics Gets $8M Grant to Work on New Gene Therapy for Vision Loss Disease In a significant milestone for the field of regenerative medicine and vision restoration, Ray Therapeutics—a clinical-stage biotechnology company specializing in optogenetic gene therapies—has been awarded…

Read MoreRay Therapeutics Gets $8M Grant to Work on New Gene Therapy for Vision Loss Disease
Kashiv BioSciences

Kashiv BioSciences Obtains $150 Million in Debt Financing from GoldenTree Asset Management

Kashiv BioSciences Obtains $150 Million in Debt Financing from GoldenTree Asset Management Kashiv BioSciences, LLC (“Kashiv” or “the Company”), a fully integrated and innovation-driven biopharmaceutical company, announced today the successful execution of a senior secured credit agreement with GoldenTree Asset…

Read MoreKashiv BioSciences Obtains $150 Million in Debt Financing from GoldenTree Asset Management
Antibody

$23.3Bn Antibody-Drug Conjugate Market Trends & Forecasts, 2035: 530+ Therapies, 140+ Developers

$23.3Bn Antibody-Drug Conjugate Market Trends & Forecasts, 2035: 530+ Therapies, 140+ Developers The antibody-drug conjugate (ADC) market is poised for significant growth, with projections indicating an increase from USD 7.72 billion in the current year to USD 23.3 billion by…

Read More$23.3Bn Antibody-Drug Conjugate Market Trends & Forecasts, 2035: 530+ Therapies, 140+ Developers